Ionis Pharmaceuticals Stock Price Target and Analyst Ratings (NASDAQ:IONS)

Analyst Price Target for IONS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$57.91

▲ +42.00% Upside Potential

This price target is based on 15 analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is $57.91, with a high forecast of $86.00 and a low forecast of $33.00. The average price target represents a 42.00% upside from the last price of $40.78.

Hold

The current consensus among 15 investment analysts is to hold stock in Ionis Pharmaceuticals. This rating has held steady since August 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
5 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

10/26/2019

0 strong buy ratings
7 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

1/24/2020

0 strong buy ratings
8 buy ratings
6 hold ratings
1 sell ratings

Ratings as of

4/23/2020

0 strong buy ratings
9 buy ratings
6 hold ratings
1 sell ratings

Ratings as of

7/22/2020

0 strong buy ratings
7 buy ratings
7 hold ratings
1 sell ratings

Ratings as of

10/20/2020

0 strong buy ratings
6 buy ratings
6 hold ratings
2 sell ratings

Ratings as of

1/18/2021

0 strong buy ratings
5 buy ratings
7 hold ratings
2 sell ratings

Ratings as of

3/19/2021

0 strong buy ratings
6 buy ratings
7 hold ratings
2 sell ratings

Ratings as of

4/18/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
4/5/2021	UBS Group	Reiterated Rating	Reduce		High	i Rating by Esther Rajavelu at UBS Group AG
3/29/2021	SVB Leerink	Lower Price Target	Market Perform	$50.00 ➝ $36.00	High	i
3/29/2021	Morgan Stanley	Lower Price Target	Underweight	$50.00 ➝ $43.00	N/A	i
3/29/2021	Needham & Company LLC	Lower Price Target	Buy	$95.00 ➝ $86.00	N/A	i
3/29/2021	BMO Capital Markets	Lower Price Target	Outperform	$90.00 ➝ $76.00	N/A	i
3/23/2021	BMO Capital Markets	Lower Price Target	Positive ➝ Outperform	$90.00 ➝ $76.00	High	i
3/23/2021	Needham & Company LLC	Lower Price Target	Buy	$95.00 ➝ $86.00	High	i
3/23/2021	SVB Leerink	Lower Price Target	Market Perform	$50.00 ➝ $36.00	High	i
3/23/2021	Morgan Stanley	Lower Price Target	Underweight	$50.00 ➝ $43.00	High	i
3/23/2021	Barclays	Lower Price Target	Equal Weight	$52.00 ➝ $47.00	High	i
3/23/2021	Royal Bank of Canada	Lower Price Target	Positive ➝ Outperform	$76.00 ➝ $65.00	High	i
3/22/2021	Piper Sandler	Lower Price Target	Neutral	$55.00 ➝ $45.00	High	i
3/16/2021	UBS Group	Reiterated Rating	Sell	$33.00	Medium	i Rating by Esther Rajavelu at UBS Group AG
3/3/2021	Morgan Stanley	Boost Price Target	Underweight	$49.00 ➝ $50.00	High	i
3/1/2021	Barclays	Upgrade	Underweight ➝ Equal Weight	$50.00 ➝ $52.00	Low	i
2/25/2021	Morgan Stanley	Boost Price Target	Underweight	$49.00 ➝ $50.00	High	i
2/24/2021	Piper Sandler	Lower Price Target	Neutral	$60.00 ➝ $55.00	High	i
12/15/2020	UBS Group	Initiated Coverage	Sell	$34.00	Medium	i
12/15/2020	Cowen	Upgrade	Market Perform ➝ Outperform		High	i
11/5/2020	Morgan Stanley	Lower Price Target	Underweight	$50.00 ➝ $49.00	High	i
11/5/2020	SVB Leerink	Lower Price Target	Market Perform	$56.00 ➝ $50.00	High	i
10/13/2020	Morgan Stanley	Lower Price Target	Underweight	$54.00 ➝ $50.00	Low	i
10/7/2020	Oppenheimer	Reiterated Rating	Buy	$69.00	Low	i Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
9/22/2020	Oppenheimer	Initiated Coverage	Buy	$69.00	High	i Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
9/22/2020	Cantor Fitzgerald	Boost Price Target	Neutral	$56.00 ➝ $59.00	High	i
9/14/2020	JPMorgan Chase & Co.	Initiated Coverage	Neutral		Medium	i
9/8/2020	Citigroup	Lower Price Target		$74.00 ➝ $78.00	Low	i
9/2/2020	Benchmark	Initiated Coverage	Hold		Medium	i
9/1/2020	Royal Bank of Canada	Boost Price Target		$71.00 ➝ $73.00	Low	i
9/1/2020	SVB Leerink	Boost Price Target	Market Perform	$54.00 ➝ $56.00	Medium	i
9/1/2020	Oppenheimer	Lower Price Target	Outperform	$74.00 ➝ $69.00	Medium	i Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
9/1/2020	Needham & Company LLC	Boost Price Target	Buy	$89.00 ➝ $91.00	Medium	i Rating by Chad Messer at Needham & Company LLC
8/30/2020	Oppenheimer	Initiated Coverage	Buy	$74.00	High	i Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
8/10/2020	Citigroup	Lower Price Target	Buy	$80.00 ➝ $78.00	High	i
8/6/2020	Morgan Stanley	Lower Price Target	Underweight	$56.00 ➝ $54.00	Low	i
8/6/2020	Oppenheimer	Reiterated Rating	Buy		Low	i
8/5/2020	Needham & Company LLC	Initiated Coverage	Buy	$89.00	Low	i Rating by Chad Messer at Needham & Company LLC
8/5/2020	William Blair	Reiterated Rating	Hold		Low	i Rating by Myles Minter at William Blair
7/15/2020	Morgan Stanley	Boost Price Target	Underweight	$51.00 ➝ $56.00	Low	i
7/15/2020	Needham & Company LLC	Reiterated Rating	Buy	$89.00	Medium	i Rating by Chad Messer at Needham & Company LLC
6/10/2020	William Blair	Reiterated Rating	Hold		High	i
6/5/2020	Citigroup	Boost Price Target	Buy	$71.00 ➝ $80.00	High	i
5/12/2020	Royal Bank of Canada	Initiated Coverage	Outperform	$71.00	Medium	i
5/7/2020	Morgan Stanley	Boost Price Target	Underweight	$48.00 ➝ $51.00	High	i
5/7/2020	Oppenheimer	Lower Price Target	Outperform	$77.00 ➝ $74.00	High	i Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
5/6/2020	Needham & Company LLC	Reiterated Rating	Buy	$89.00	High	i Rating by Chad Messer at Needham & Company LLC
4/9/2020	Citigroup	Lower Price Target	Buy	$73.00 ➝ $71.00	Low	i
3/26/2020	Cantor Fitzgerald	Lower Price Target	Neutral	$65.00 ➝ $56.00	High	i Rating by Eliana Merle at Cantor Fitzgerald
3/9/2020	JPMorgan Chase & Co.	Boost Price Target	Neutral	$58.00 ➝ $60.00	Low	i
3/5/2020	Citigroup	Initiated Coverage	Buy	$73.00	High	i
2/27/2020	Piper Sandler	Lower Price Target	Neutral	$70.00 ➝ $65.00	High	i
1/30/2020	BMO Capital Markets	Reiterated Rating	Buy	$86.00	High	i Rating by Do Kim at BMO Capital Markets
1/24/2020	William Blair	Reiterated Rating	Hold		Low	i Rating by M. Minter at William Blair
12/31/2019	Bank of America	Reiterated Rating	Buy	$70.00	Medium	i Rating by Jason Gerberry at Bank of America Co.
12/23/2019	Needham & Company LLC	Reiterated Rating	Buy	$87.00	Low	i Rating by Chad Messer at Needham & Company LLC
12/13/2019	Needham & Company LLC	Reiterated Rating	Buy	$87.00	Medium	i Rating by Chad Messer at Needham & Company LLC
12/12/2019	Oppenheimer	Initiated Coverage	Buy	$77.00	Low	i Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
11/14/2019	William Blair	Initiated Coverage	Market Perform		Low	i Rating by M. Minter at William Blair
11/13/2019	Bank of America	Initiated Coverage	Buy	$70.00	Medium	i
11/7/2019	Piper Jaffray Companies	Lower Price Target	Neutral	$75.00 ➝ $70.00	Medium	i Rating by Tyler Van Buren at Piper Jaffray Companies
11/7/2019	Needham & Company LLC	Reiterated Rating	Buy	$87.00	Low	i Rating by Chad Messer at Needham & Company LLC
11/7/2019	Morgan Stanley	Downgrade	Equal ➝ Equal Weight	$63.00 ➝ $48.00	Low	i Rating by David Lebovitz at Morgan Stanley
11/7/2019	Cowen	Reiterated Rating	Hold		Low	i
10/16/2019	Cowen	Reiterated Rating	Hold		High	i
10/15/2019	Cantor Fitzgerald	Set Price Target	Hold	$65.00	N/A	i Rating by Eliana Merle at Cantor Fitzgerald
10/11/2019	Morgan Stanley	Lower Price Target	Equal Weight	$68.00 ➝ $63.00	Medium	i
10/10/2019	Wells Fargo & Company	Boost Price Target	Outperform	$90.00 ➝ $120.00	Medium	i
10/9/2019	Needham & Company LLC	Set Price Target	Buy	$87.00	Low	i Rating by Chad Messer at Needham & Company LLC
9/23/2019	Wells Fargo & Company	Reiterated Rating	Buy		Medium	i
9/10/2019	Sanford C. Bernstein	Upgrade	Market Perform ➝ Outperform	$80.00	High	i
8/7/2019	Evercore ISI	Set Price Target	Hold	$76.00	Low	i Rating by Joshua Schimmer at Evercore ISI
7/24/2019	BMO Capital Markets	Lower Price Target	Outperform	$96.00 ➝ $95.00	Low	i
5/24/2019	Piper Jaffray Companies	Set Price Target	Hold	$75.00	Medium	i Rating by Tyler Van Buren at Piper Jaffray Companies
4/24/2019	Cantor Fitzgerald	Reiterated Rating	Hold	$68.00	Low	i Rating by E. Merle at Cantor Fitzgerald
4/22/2019	BMO Capital Markets	Boost Price Target	Outperform	$96.00	Low	i
4/18/2019	Cantor Fitzgerald	Reiterated Rating	Hold		Low	i Rating by E. Merle at Cantor Fitzgerald
4/9/2019	Cantor Fitzgerald	Initiated Coverage	Neutral	$68.00	Medium	i Rating by E. Merle at Cantor Fitzgerald
3/22/2019	Piper Jaffray Companies	Set Price Target	Neutral	$63.00 ➝ $75.00	Low	i Rating by Tyler Van Buren at Piper Jaffray Companies
3/18/2019	JPMorgan Chase & Co.	Boost Price Target	Neutral ➝ Neutral	$47.00 ➝ $55.00	Low	i
3/1/2019	Morgan Stanley	Set Price Target	Hold	$71.00	Low	i Rating by David Lebovitz at Morgan Stanley
3/1/2019	Piper Jaffray Companies	Set Price Target	Hold	$63.00	Low	i Rating by Tyler Van Buren at Piper Jaffray Companies
2/28/2019	Piper Jaffray Companies	Boost Price Target	Neutral	$60.00	Low	i Rating by Tyler Van Buren at Piper Jaffray Companies
2/28/2019	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$70.00 ➝ $82.00	Low	i
11/27/2018	SVB Leerink	Initiated Coverage	Market Perform	$50.00	High	i Rating by M. Foroohar at SVB Leerink LLC
11/7/2018	Morgan Stanley	Set Price Target	Hold	$46.00	Low	i Rating by David Lebovitz at Morgan Stanley
11/6/2018	Piper Jaffray Companies	Set Price Target	Hold	$50.00	Medium	i Rating by Tyler Van Buren at Piper Jaffray Companies
10/3/2018	Morgan Stanley	Set Price Target	Hold	$45.00	Low	i Rating by David Lebovitz at Morgan Stanley
9/25/2018	Stifel Nicolaus	Boost Price Target	Hold ➝ Hold	$45.00 ➝ $48.00	High	i
9/24/2018	Piper Jaffray Companies	Set Price Target	Hold	$50.00	Medium	i Rating by Tyler Van Buren at Piper Jaffray Companies
8/28/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$49.00 ➝ $45.00	Low	i
8/28/2018	Stifel Nicolaus	Lower Price Target	Hold ➝ Hold	$47.00 ➝ $45.00	High	i
8/8/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$51.00 ➝ $49.00	High	i
8/7/2018	Stifel Nicolaus	Lower Price Target	Hold ➝ Hold	$55.00 ➝ $48.00	High	i
7/11/2018	Piper Jaffray Companies	Set Price Target	Hold	$50.00	Low	i Rating by Tyler Van Buren at Piper Jaffray Companies
6/20/2018	Barclays	Downgrade	Equal Weight ➝ Underweight	$52.00	High	i
5/30/2018	Piper Jaffray Companies	Initiated Coverage	Hold	$50.00	Medium	i Rating by Tyler Van Buren at Piper Jaffray Companies
5/7/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$52.00	Low	i
5/7/2018	Stifel Nicolaus	Lower Price Target	Hold ➝ Hold	$57.00	Low	i
4/23/2018	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$70.00 ➝ $75.00	Medium	i
2/28/2018	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$64.00 ➝ $65.00	High	i
2/28/2018	Stifel Nicolaus	Boost Price Target	Hold ➝ Hold	$55.00 ➝ $57.00	High	i
2/20/2018	Sanford C. Bernstein	Reiterated Rating	Market Perform	$61.00 ➝ $55.00	Low	i
11/8/2017	BMO Capital Markets	Boost Price Target	Outperform	$64.00 ➝ $65.00	N/A	i
11/8/2017	Morgan Stanley	Boost Price Target	Equal Weight	$45.00 ➝ $49.00	N/A	i
10/17/2017	Needham & Company LLC	Reiterated Rating	Buy	$64.00	N/A	i
10/13/2017	Stifel Nicolaus	Reiterated Rating	Hold	$50.00	N/A	i
10/6/2017	The Goldman Sachs Group	Reiterated Rating	Sell ➝ Sell	$30.00	N/A	i
10/2/2017	BMO Capital Markets	Reiterated Rating	Outperform	$69.00	Medium	i
9/21/2017	Barclays	Lower Price Target	Equal Weight	$55.00 ➝ $52.00	Low	i
9/17/2017	Needham & Company LLC	Reiterated Rating	Buy	$64.00	Low	i
9/12/2017	Stifel Nicolaus	Reiterated Rating	Hold		Low	i
9/6/2017	Barclays	Initiated Coverage	Equal Weight	$55.00	Medium	i
8/16/2017	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$65.00	Low	i
8/14/2017	Laidlaw	Reiterated Rating	Buy	$65.00	Low	i
8/14/2017	BMO Capital Markets	Boost Price Target	Outperform	$67.00 ➝ $69.00	Low	i
8/10/2017	Jefferies Financial Group	Reiterated Rating	Underperform	$17.00 ➝ $18.00	High	i
8/9/2017	Stifel Nicolaus	Boost Price Target	Hold	$42.00 ➝ $50.00	Low	i
7/27/2017	Sanford C. Bernstein	Initiated Coverage	Market Perform	$57.00	High	i
7/26/2017	Needham & Company LLC	Reiterated Rating	Buy	$64.00	Medium	i
7/25/2017	BMO Capital Markets	Reiterated Rating	Outperform	$59.56 ➝ $62.00	Low	i
7/12/2017	BMO Capital Markets	Reiterated Rating	Outperform	$59.00 ➝ $62.00	Low	i
7/10/2017	Stifel Nicolaus	Reiterated Rating	Hold	$42.00	Medium	i
6/2/2017	BMO Capital Markets	Reiterated Rating	Buy	$59.00	Medium	i Rating by Do Kim at BMO Capital Markets
5/22/2017	Cowen	Reiterated Rating	Market Perform		Low	i
5/17/2017	SVB Leerink	Reiterated Rating	Outperform	$47.00 ➝ $45.00	Medium	i
5/17/2017	Needham & Company LLC	Reiterated Rating	Buy	$64.00	Low	i
5/11/2017	BMO Capital Markets	Boost Price Target	Outperform	$32.00 ➝ $35.00	High	i Rating by Do Kim at BMO Capital Markets
5/10/2017	Piper Jaffray Companies	Set Price Target	Buy	$66.00 ➝ $51.00	Low	i Rating by Joshua Schimmer at Piper Jaffray Companies
4/26/2017	BMO Capital Markets	Reiterated Rating	Outperform	$59.00	Low	i Rating by Do Kim at BMO Capital Markets
3/10/2017	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$28.00 ➝ $25.00	High	i
3/7/2017	BMO Capital Markets	Lower Price Target	Outperform	$63.00 ➝ $59.00	N/A	i Rating by Do Kim at BMO Capital Markets
3/6/2017	Needham & Company LLC	Reiterated Rating	Buy	$64.00	N/A	i
2/28/2017	Needham & Company LLC	Reiterated Rating	Buy	$64.00	N/A	i
2/14/2017	BMO Capital Markets	Reiterated Rating	Outperform ➝ Positive	$63.00	N/A	i Rating by Do Kim at BMO Capital Markets
1/17/2017	BMO Capital Markets	Reiterated Rating	Outperform	$68.00 ➝ $63.00	N/A	i Rating by Do Kim at BMO Capital Markets
1/8/2017	BMO Capital Markets	Reiterated Rating	Outperform	$68.00	N/A	i Rating by Do Kim at BMO Capital Markets
1/8/2017	Needham & Company LLC	Reiterated Rating	Buy	$64.00	N/A	i Rating by Chad Messer at Needham & Company LLC
1/6/2017	Cowen	Reiterated Rating	Hold		N/A	i Rating by Eric Schmidt at Cowen Inc
1/6/2017	Jefferies Financial Group	Reiterated Rating	Sell	$17.00	N/A	i
1/5/2017	Janney Montgomery Scott	Set Price Target	Hold	$44.00	N/A	i Rating by Debjit Chattopadhyay at Janney Montgomery Scott
12/28/2016	Janney Montgomery Scott	Reiterated Rating	Neutral	$50.00 ➝ $54.00	N/A	i
12/28/2016	BMO Capital Markets	Boost Price Target	Outperform	$61.00 ➝ $68.00	N/A	i Rating by Do Kim at BMO Capital Markets
12/27/2016	Needham & Company LLC	Reiterated Rating	Buy	$64.00	N/A	i Rating by Chad Messer at Needham & Company LLC
12/27/2016	Laidlaw	Boost Price Target	Buy	$59.00 ➝ $65.00	N/A	i
12/27/2016	SVB Leerink	Boost Price Target	Market Perform	$40.00 ➝ $47.00	N/A	i Rating by P. Matteis at SVB Leerink LLC
12/20/2016	BMO Capital Markets	Set Price Target	Buy	$48.00 ➝ $61.00	N/A	i Rating by Do Kim at BMO Capital Markets
11/10/2016	JPMorgan Chase & Co.	Reiterated Rating	Hold	$35.00	N/A	i Rating by Jessica Fye at JPMorgan Chase & Co.
11/10/2016	SVB Leerink	Reiterated Rating	Market Perform	$40.00	N/A	i Rating by P. Matteis at SVB Leerink LLC
11/10/2016	Jefferies Financial Group	Reiterated Rating	Sell	$17.00	N/A	i Rating by Eun Yang at Jefferies Financial Group Inc.
11/9/2016	Piper Jaffray Companies	Reiterated Rating	Buy		N/A	i Rating by joshua schimmer at Piper Jaffray Companies
11/8/2016	BMO Capital Markets	Reiterated Rating	Buy	$48.00	N/A	i Rating by Do Kim at BMO Capital Markets
10/17/2016	BMO Capital Markets	Reiterated Rating	Outperform	$48.00	N/A	i Rating by Do Kim at BMO Capital Markets
10/6/2016	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$42.00 ➝ $48.00	N/A	i Rating by Do Kim at BMO Capital Markets
9/28/2016	Janney Montgomery Scott	Initiated Coverage	Buy	$47.00	N/A	i
9/26/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$46.00	N/A	i Rating by joshua schimmer at Piper Jaffray Companies
9/11/2016	Wells Fargo & Company	Reiterated Rating	Buy		N/A	i Rating by Jim Birchenough at Wells Fargo & Company
8/19/2016	Wells Fargo & Company	Reiterated Rating	Outperform		N/A	i Rating by Jim Birchenough at Wells Fargo & Company
8/18/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$46.00	N/A	i Rating by joshua schimmer at Piper Jaffray Companies
8/13/2016	Cowen	Reiterated Rating	Market Perform		N/A	i Rating by Eric Schmidt at Cowen Inc
8/11/2016	SVB Leerink	Reiterated Rating	Hold	$36.00	N/A	i Rating by Michael Schmidt at SVB Leerink LLC
8/10/2016	Piper Jaffray Companies	Boost Price Target	Overweight	$36.00 ➝ $46.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
8/3/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Eric Schmidt at Cowen Inc
8/2/2016	SVB Leerink	Reiterated Rating	Market Perform	$26.00 ➝ $36.00	N/A	i Rating by Michael Schmidt at SVB Leerink LLC
8/2/2016	Barclays	Boost Price Target	Equal Weight	$26.00 ➝ $41.00	N/A	i
8/2/2016	Morgan Stanley	Initiated Coverage	Equal ➝ Equal Weight	$37.00 ➝ $37.00	N/A	i
8/1/2016	BMO Capital Markets	Boost Price Target	Market Perform	$25.00 ➝ $40.00	N/A	i Rating by Do Kim at BMO Capital Markets
8/1/2016	Needham & Company LLC	Boost Price Target	Buy	$55.00 ➝ $64.00	N/A	i Rating by Chad Messer at Needham & Company LLC
7/18/2016	SVB Leerink	Reiterated Rating	Market Perform	$39.00 ➝ $26.00	N/A	i Rating by Michael Schmidt at SVB Leerink LLC
7/15/2016	Jefferies Financial Group	Reiterated Rating	Underperform	$12.00	N/A	i Rating by Eun Yang at Jefferies Financial Group Inc.
7/15/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$35.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
7/14/2016	Needham & Company LLC	Reiterated Rating	Buy	$55.00	N/A	i Rating by Chad Messer at Needham & Company LLC
7/14/2016	Cowen	Reiterated Rating	Hold		N/A	i Rating by Eric Schmidt at Cowen Inc
7/8/2016	Needham & Company LLC	Reiterated Rating	Buy	$55.00	N/A	i Rating by Chad Messer at Needham & Company LLC
7/8/2016	BMO Capital Markets	Reiterated Rating	Market Perform	$26.00	N/A	i Rating by Do Kim at BMO Capital Markets
6/10/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$35.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
6/7/2016	Needham & Company LLC	Reiterated Rating	Buy	$55.00	N/A	i Rating by Chad Messer at Needham & Company LLC
6/7/2016	BMO Capital Markets	Reiterated Rating	Market Perform	$26.00	N/A	i Rating by Do Kim at BMO Capital Markets
5/29/2016	JPMorgan Chase & Co.	Reiterated Rating	Hold		N/A	i Rating by Jessica Fye at JPMorgan Chase & Co.
5/29/2016	Jefferies Financial Group	Reiterated Rating	Sell		N/A	i Rating by Eun Yang at Jefferies Financial Group Inc.
5/27/2016	JPMorgan Chase & Co.	Lower Price Target	Neutral	$53.00 ➝ $25.00	N/A	i
5/27/2016	Barclays	Lower Price Target	Equal Weight	$42.00 ➝ $26.00	N/A	i
5/27/2016	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$55.00 ➝ $26.00	N/A	i
5/26/2016	Piper Jaffray Companies	Reiterated Rating	Buy		N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
5/26/2016	Cowen	Reiterated Rating	Outperform ➝ Hold		N/A	i Rating by Eric Schmidt at Cowen Inc
5/26/2016	Needham & Company LLC	Reiterated Rating	Buy	$88.00 ➝ $55.00	N/A	i
5/19/2016	Wells Fargo & Company	Reiterated Rating	Buy		N/A	i
5/5/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$60.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
5/5/2016	SVB Leerink	Lower Price Target	Market Perform	$40.00 ➝ $39.00	N/A	i Rating by Michael Schmidt at SVB Leerink LLC
5/4/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Eric Schmidt at Cowen Inc
5/2/2016	JPMorgan Chase & Co.	Reiterated Rating	Hold		N/A	i

(Data available from 4/19/2016 forward)

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Today's Range

Now: $40.78

$40.20

$41.31

50 Day Range

MA: $48.57

$40.87

$55.64

52 Week Range

Now: $40.78

$40.20

$64.37

Volume

1,860,200 shs

Average Volume

1,221,907 shs

Market Capitalization

$5.74 billion

P/E Ratio

84.96

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Ionis Pharmaceuticals?

The following equities research analysts have issued research reports on Ionis Pharmaceuticals in the last year: Barclays PLC, Benchmark Co., BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Cowen Inc, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, SVB Leerink LLC, TheStreet, UBS Group AG, William Blair, and Zacks Investment Research.
View the latest analyst ratings for IONS.

What is the current price target for Ionis Pharmaceuticals?

11 Wall Street analysts have set twelve-month price targets for Ionis Pharmaceuticals in the last year. Their average twelve-month price target is $57.91, suggesting a possible upside of 42.0%. Needham & Company LLC has the highest price target set, predicting IONS will reach $86.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $33.00 for Ionis Pharmaceuticals in the next year.
View the latest price targets for IONS.

What is the current consensus analyst rating for Ionis Pharmaceuticals?

Ionis Pharmaceuticals currently has 2 sell ratings, 7 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IONS, but not buy more shares or sell existing shares.
View the latest ratings for IONS.

What other companies compete with Ionis Pharmaceuticals?

Other companies that are similar to Ionis Pharmaceuticals include Amgen, Gilead Sciences, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Biogen, Alexion Pharmaceuticals, Seagen, Exact Sciences, Incyte, Novavax, Alnylam Pharmaceuticals, BioMarin Pharmaceutical, Repligen, Neurocrine Biosciences and United Therapeutics.

How do I contact Ionis Pharmaceuticals' investor relations team?

Ionis Pharmaceuticals' physical mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company's listed phone number is 760-931-9200 and its investor relations email address is [email protected] The official website for Ionis Pharmaceuticals is www.ionispharma.com.

NASDAQ:IONS - Ionis Pharmaceuticals Stock Price Target and Predictions

Analyst Price Target for IONS

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Ionis Pharmaceuticals?

What is the current price target for Ionis Pharmaceuticals?

What is the current consensus analyst rating for Ionis Pharmaceuticals?

What other companies compete with Ionis Pharmaceuticals?

How do I contact Ionis Pharmaceuticals' investor relations team?